Dulaglutide vs Cagrilintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Trulicity
Dulaglutide (brand name Trulicity) is a once-weekly injectable GLP-1 receptor agonist made by fusing a modified GLP-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. It is FDA-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. The once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents.
Also: AM833, NN9838
Cagrilintide (also called AM833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. It is an investigational once-weekly injectable being developed by Novo Nordisk for obesity, most prominently as the amylin half of CagriSema (cagrilintide plus semaglutide). It is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development.
Key Comparison Insights
- Dulaglutide is FDA approved, while Cagrilintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Dulaglutide has stronger research evidence (FDA Approved) compared to Cagrilintide (Human Trials).
Detailed Comparison
| Attribute | Dulaglutide | Cagrilintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dulaglutide activates the GLP-1 receptor, mimicking the natural incretin hormone your gut releases after eating. It prompts glucose-dependent insulin release, suppresses glucagon, and slows gastric emptying, so blood sugar drops after meals without driving dangerous lows. The antibody (Fc) portion bolted onto the peptide makes the molecule too large for the kidneys to quickly clear and shields it from the DPP-4 enzyme that destroys natural GLP-1 within minutes. That engineering is the entire reason a once-weekly schedule works. The appetite and modest weight effects come from the same GLP-1 signaling in brain regions that regulate hunger. | Cagrilintide is a non-selective agonist of the amylin and calcitonin receptor family. It activates amylin receptors (which are calcitonin receptors paired with RAMP accessory proteins) to signal satiety in the brain, slow gastric emptying, and blunt the post-meal glucagon rise. Mechanistic work in mice shows it reduces body weight mainly through amylin receptors AMY1R and AMY3R acting in the hindbrain, with the area postrema as a key entry point and downstream signaling through the nucleus of the solitary tract and parabrachial nucleus. Notably, weight loss in those studies persisted even after the acute appetite-suppressing effect faded, hinting at effects on energy balance beyond simple food-intake reduction. Chemically it is built on a pramlintide-like 37-amino-acid backbone with substitutions and a fatty-diacid chain attached to extend its half-life to roughly a week, enabling once-weekly dosing. |
| Common Dosing | 1.5-4.5 mg weekly Once weekly | 2.4 mg weekly Once weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection once weekly |
| Typical Duration | Long-term / chronic use | Long-term / chronic use expected |
| Best Time to Take | Before bed or morning (fasted) | Any consistent time weekly |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Dulaglutide is backed by extensive human trials, not animal models. The AWARD program established its glucose-lowering efficacy across many type 2 diabetes settings. The landmark REWIND trial, published in The Lancet in 2019, followed over 9,900 patients for a median of more than five years and was unusual because most participants (about 69%) had no prior cardiovascular disease. It found dulaglutide reduced major cardiovascular events (cardiovascular death, heart attack, or stroke) versus placebo, 12.0% vs 13.4%, a hazard ratio of 0.88. That made it one of the first GLP-1 agents with evidence supporting both primary and secondary cardiovascular prevention. The typical downsides are gastrointestinal (nausea, diarrhea), and like others in the class it carries a boxed warning about thyroid C-cell tumors based on rodent data. | Cagrilintide has real human data, which sets it apart from most peptides in this category. In a 2021 Lancet phase 2 dose-finding trial (Lau et al.), once-weekly cagrilintide at 4.5 mg produced about 10.8% mean body weight loss over 26 weeks, beating both placebo (around 3%) and liraglutide 3.0 mg (around 9%), establishing that amylin agonism alone can drive clinically meaningful weight loss. Its bigger story is combination therapy: paired with semaglutide as CagriSema, it advanced into phase 3 REDEFINE trials for obesity and type 2 diabetes, with reported weight loss in the low 20% range, though final results came in somewhat below the most optimistic expectations. Side effects are dominated by the expected gastrointestinal effects (nausea, vomiting) common to gut-hormone drugs. As of 2026 cagrilintide is investigational and not FDA-approved on its own. The evidence is genuinely human and well-controlled here, which is rare, but it is still a drug under regulatory review rather than an approved therapy. |
Frequently Asked Questions: Dulaglutide vs Cagrilintide
What is the difference between Dulaglutide and Cagrilintide?
Dulaglutide is a weight loss peptide that dulaglutide (brand name trulicity) is a once-weekly injectable glp-1 receptor agonist made by fusing a modified glp-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. it is fda-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. the once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents. Cagrilintide is a weight loss peptide that cagrilintide (also called am833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. it is an investigational once-weekly injectable being developed by novo nordisk for obesity, most prominently as the amylin half of cagrisema (cagrilintide plus semaglutide). it is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dulaglutide or Cagrilintide?
Neither is universally "better" - the choice depends on your specific goals. Dulaglutide is typically used for weight loss purposes, while Cagrilintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dulaglutide and Cagrilintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dulaglutide and Cagrilintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.